Tesla Stock Has 71% Upside, According to 1 Wall Street Analyst
Published
After a dismal performance so far in 2024, a $300 price target might seem like a stretch. Is the stock finally a buy?
Full ArticlePublished
After a dismal performance so far in 2024, a $300 price target might seem like a stretch. Is the stock finally a buy?
Full ArticleBiotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.
Will these catalysts be enough to support the stock's high valuation?